Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Melanoma immunotherapy.
Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S. Sanlorenzo M, et al. Among authors: algazi a. Cancer Biol Ther. 2014 Jun 1;15(6):665-74. doi: 10.4161/cbt.28555. Epub 2014 Mar 20. Cancer Biol Ther. 2014. PMID: 24651672 Free PMC article. Review.
Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.
DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, Daud AI. DeConti RC, et al. Among authors: algazi ap. Br J Cancer. 2010 Nov 9;103(10):1548-53. doi: 10.1038/sj.bjc.6605931. Epub 2010 Oct 5. Br J Cancer. 2010. PMID: 20924376 Free PMC article. Clinical Trial.
NRAS-mutant melanoma: response to chemotherapy.
Soon CW, Algazi AP, Cha EN, Webb EM, Daud AI. Soon CW, et al. Arch Dermatol. 2011 May;147(5):626-7. doi: 10.1001/archdermatol.2011.85. Arch Dermatol. 2011. PMID: 21576590 No abstract available.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Hamid O, et al. Among authors: algazi a. N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2. N Engl J Med. 2013. PMID: 23724846 Free PMC article. Clinical Trial.
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Johnson DB, et al. Among authors: algazi a. J Clin Oncol. 2014 Nov 20;32(33):3697-704. doi: 10.1200/JCO.2014.57.3535. Epub 2014 Oct 6. J Clin Oncol. 2014. PMID: 25287827 Free PMC article. Clinical Trial.
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. Sanlorenzo M, et al. Among authors: algazi a. J Am Acad Dermatol. 2014 Dec;71(6):1102-1109.e1. doi: 10.1016/j.jaad.2014.09.002. Epub 2014 Oct 16. J Am Acad Dermatol. 2014. PMID: 25440439 Free PMC article.
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. Moriceau G, et al. Among authors: algazi a. Cancer Cell. 2015 Feb 9;27(2):240-56. doi: 10.1016/j.ccell.2014.11.018. Epub 2015 Jan 15. Cancer Cell. 2015. PMID: 25600339 Free PMC article.
90 results